3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Sezary Syndrome
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Carcinoma, Hepatocellular
1
Interventions
mogamulizumab
4
denileukin diftitox
4
Vorinostat
4
Panobinostat
4
zanolimumab
3
cobomarsen
3
Brentuximab Vedotin
3
Bexarotene
3
tenalisib
2
selinexor
2
marizomib
2
hypericin
2
Vitamin B 12
2
Rituximab
2
Folic Acid
2
A-dmDT390-bisFv(UCHT1) protein
2
10-propargyl-10-deazaaminopterin
2
tislelizumab
1
tinostamustine
1
sapacitabine
1
romidepsin
1
resminostat
1
quisinostat
1
ontuxizumab
1
navitoclax
1
forodesine
1
fludarabine phosphate
1
enzastaurin
1
belinostat
1
abexinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Cutaneous
×
resminostat
×
Clear all
NCT02953301
2024-08-30
RESMAIN
4SC AG
Phase 2
Completed
201 enrolled